Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Roy M Gulick

Showing results (11-20 of 155) with videos related to

Pageof 16
Sort By:
Annual Review of Medicine|October 26, 2018
Long-Acting HIV Drugs for Treatment and PreventionRoy M Gulick, Charles Flexner
Current Opinion in HIV and AIDS|November 19, 2024
Future options for long-acting HIV treatment and preventionYotam Arens, Roy M Gulick
Current Opinion in HIV and AIDS|October 29, 2019
HIV treatment and prevention 2019: current standards of careNittaya Phanuphak, Roy M Gulick
Current Infectious Disease Reports|July 22, 2004
New Antiretroviral Agents for the Treatment of HIV InfectionKristen Marks, Roy M. Gulick
Current Infectious Disease Reports|April 14, 2007
New antiretroviral agentsLawrence Siegel, Roy M Gulick
Current Infectious Disease Reports|April 5, 2001
New Drugs for the Treatment of HIV InfectionKristin Lee, Roy M. Gulick
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|February 24, 2009
Raltegravir: the first HIV type 1 integrase inhibitorCharles Hicks, Roy M Gulick
Annual Review of Medicine|November 1, 2011
CCR5 antagonism in HIV infection: current concepts and future opportunitiesTimothy J Wilkin, Roy M Gulick
Annals of Internal Medicine|October 26, 2021
Managing HIV Treatment Failure: Time to REVAMP?Roy M Gulick, Marshall J Glesby
Annals of Internal Medicine|July 5, 2021
HIV: Closing the Mortality GapMarshall J Glesby, Roy M Gulick
Pageof 16

Showing results (11-20 of 155) with videos related to

Sort By:
Pageof 16
Annual Review of Medicine|October 26, 2018
Long-Acting HIV Drugs for Treatment and PreventionRoy M Gulick, Charles Flexner
Current Opinion in HIV and AIDS|November 19, 2024
Future options for long-acting HIV treatment and preventionYotam Arens, Roy M Gulick
Current Opinion in HIV and AIDS|October 29, 2019
HIV treatment and prevention 2019: current standards of careNittaya Phanuphak, Roy M Gulick
Current Infectious Disease Reports|July 22, 2004
New Antiretroviral Agents for the Treatment of HIV InfectionKristen Marks, Roy M. Gulick
Current Infectious Disease Reports|April 14, 2007
New antiretroviral agentsLawrence Siegel, Roy M Gulick
Current Infectious Disease Reports|April 5, 2001
New Drugs for the Treatment of HIV InfectionKristin Lee, Roy M. Gulick
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|February 24, 2009
Raltegravir: the first HIV type 1 integrase inhibitorCharles Hicks, Roy M Gulick
Annual Review of Medicine|November 1, 2011
CCR5 antagonism in HIV infection: current concepts and future opportunitiesTimothy J Wilkin, Roy M Gulick
Annals of Internal Medicine|October 26, 2021
Managing HIV Treatment Failure: Time to REVAMP?Roy M Gulick, Marshall J Glesby
Annals of Internal Medicine|July 5, 2021
HIV: Closing the Mortality GapMarshall J Glesby, Roy M Gulick
Pageof 16